These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 23688955)

  • 1. Metabolomics in rheumatic diseases: the potential of an emerging methodology for improved patient diagnosis, prognosis, and treatment efficacy.
    Priori R; Scrivo R; Brandt J; Valerio M; Casadei L; Valesini G; Manetti C
    Autoimmun Rev; 2013 Aug; 12(10):1022-30. PubMed ID: 23688955
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolomics approach in allergic and rheumatic diseases.
    Scrivo R; Casadei L; Valerio M; Priori R; Valesini G; Manetti C
    Curr Allergy Asthma Rep; 2014 Jun; 14(6):445. PubMed ID: 24744271
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emerging role of metabolomics in rheumatology.
    Gupta L; Ahmed S; Jain A; Misra R
    Int J Rheum Dis; 2018 Aug; 21(8):1468-1477. PubMed ID: 30146741
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metabolomics in rheumatic diseases: desperately seeking biomarkers.
    Guma M; Tiziani S; Firestein GS
    Nat Rev Rheumatol; 2016 May; 12(5):269-81. PubMed ID: 26935283
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genomics, proteomics and metabolomics: their emerging roles in the discovery and validation of rheumatoid arthritis biomarkers.
    Castro-Santos P; Laborde CM; Díaz-Peña R
    Clin Exp Rheumatol; 2015; 33(2):279-86. PubMed ID: 25572119
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The applied basic research of systemic lupus erythematosus based on the biological omics.
    Sui W; Hou X; Che W; Yang M; Dai Y
    Genes Immun; 2013 Apr; 14(3):133-46. PubMed ID: 23446742
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolic changes in autoimmune diseases.
    Seeger K
    Curr Drug Discov Technol; 2009 Dec; 6(4):256-61. PubMed ID: 20025593
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mining the Proteome Associated with Rheumatic and Autoimmune Diseases.
    Ruiz-Romero C; Lam MPY; Nilsson P; Önnerfjord P; Utz PJ; Van Eyk JE; Venkatraman V; Fert-Bober J; Watt FE; Blanco FJ
    J Proteome Res; 2019 Dec; 18(12):4231-4239. PubMed ID: 31599600
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Application of metabolomics in autoimmune diseases: insight into biomarkers and pathology.
    Kang J; Zhu L; Lu J; Zhang X
    J Neuroimmunol; 2015 Feb; 279():25-32. PubMed ID: 25669996
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lymphocytes as Biomarkers of Therapeutic Response in Rheumatic Autoimmune Diseases, Is It a Realistic Goal?
    Schreiber K; Nocturne G; Cornec D; Daïen CI
    Clin Rev Allergy Immunol; 2017 Oct; 53(2):277-290. PubMed ID: 28560621
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mixing omics: combining genetics and metabolomics to study rheumatic diseases.
    Menni C; Zierer J; Valdes AM; Spector TD
    Nat Rev Rheumatol; 2017 Mar; 13(3):174-181. PubMed ID: 28148918
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnostic and prognostic tests in systemic lupus erythematosus.
    Vasquez-Canizares N; Wahezi D; Putterman C
    Best Pract Res Clin Rheumatol; 2017 Jun; 31(3):351-363. PubMed ID: 29224677
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Metabolomics for Biomarker Discovery in Systemic Lupus Erythematosus].
    Saegusa J; Kawano S; Morinobu A
    Rinsho Byori; 2015 Apr; 63(4):498-505. PubMed ID: 26536784
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 5-Methylcytosine content of DNA in blood, synovial mononuclear cells and synovial tissue from patients affected by autoimmune rheumatic diseases.
    Corvetta A; Della Bitta R; Luchetti MM; Pomponio G
    J Chromatogr; 1991 May; 566(2):481-91. PubMed ID: 1939459
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cell-Free DNA as a Biomarker in Autoimmune Rheumatic Diseases.
    Duvvuri B; Lood C
    Front Immunol; 2019; 10():502. PubMed ID: 30941136
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Endothelial dysfunction in rheumatic autoimmune diseases.
    Murdaca G; Colombo BM; Cagnati P; Gulli R; Spanò F; Puppo F
    Atherosclerosis; 2012 Oct; 224(2):309-17. PubMed ID: 22673743
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Application of omics in predicting anti-TNF efficacy in rheumatoid arthritis.
    Xie X; Li F; Li S; Tian J; Chen JW; Du JF; Mao N; Chen J
    Clin Rheumatol; 2018 Jan; 37(1):13-23. PubMed ID: 28600618
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Integration of metabolomics and transcriptomics in nanotoxicity studies.
    Shin TH; Lee DY; Lee HS; Park HJ; Jin MS; Paik MJ; Manavalan B; Mo JS; Lee G
    BMB Rep; 2018 Jan; 51(1):14-20. PubMed ID: 29301609
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of Semaphorins in Immunopathologies and Rheumatic Diseases.
    Garcia S
    Int J Mol Sci; 2019 Jan; 20(2):. PubMed ID: 30654587
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.